Copyright © Inderes 2011 - present. All rights reserved.
Log in to your Inderes Free account to see all free content on this page.
Create account

Aiforia Technologies

2.33 EUR

+2.64 %

2,149 following
Corporate customer

AIFORIA

First North Finland

Medical Equipment & Services

Health Care

+2.64 %
+2.19 %
-6.43 %
-17.38 %
-30.65 %
-35.99 %
-33.33 %
-
-53.95 %

Aiforia Technologies equips pathologists and researchers in preclinical and clinical laboratories with software to translate images into discoveries, decisions and diagnoses. The company's products and services are used for medical image analysis, across a variety of fields such as oncology and neuroscience. Aiforia Technologies is headquartered in Finland.

Read more
Market cap
78.3M EUR
Turnover
24.57K EUR
P/E (adj.) (25e)
EV/EBIT (adj.) (25e)
P/B (25e)
EV/S (25e)
Dividend yield-% (25e)
Coverage
Recommendation
Accumulate
Target price
Updated
19.11.2025
Disclaimer
Frans-Mikael Rostedt
Antti Luiro
Antti Luiro, Frans-Mikael Rostedt
Show more
Latest research

Latest analysis report

Released: 19.11.2025

Latest extensive report

Released: 24.04.2025

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
6.3.
2026

Annual report '25

2.4.
2026

General meeting '26

28.8.
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio
Create account
Forum discussions
Aiforia’s new shareholder list. Kyösti Kakkonen (Joensuun Kauppa Ja Kone Oy) as a new owner directly at 30th place. Aiforia Aiforia - Osakkeenomistajat Aiforia on lääketieteen ohjelmistoyritys, joka tarjoaa patologeille ja tutkijoille kliinisissä, prekliinisissä ja akateemisissa ...
1/2/2026, 12:38 PM
by TO
39
Hospitalia, le magazine de l'hôpital pour toute l'actualité et l'information... Le CHU de Nantes franchit le cap du numérique en anatomie pathologique Le CHU de Nantes vient de franchir une étape décisive dans la transformation numérique de ses pratiques en anatomie pathologique....
1/22/2026, 4:09 PM
by Jekkku
31
What is the final result when you combine the strong growth outlook of AI with a conservative industry and its inherent sluggishness? pathologynews.com Digital Pathology Market Growing at 9.9% CAGR to 2031 as AI Adoption... /PRNewswire/ -- According to Mordor Intelligence, the digital...
1/20/2026, 12:19 PM
by Vino Pino
26
Inderes’ extensive report: “In the United States, the customer can also self-validate an AI model they have developed for clinical use (referred to in the US by the term LDT, Lab Developed Test). In these cases, Aiforia sells its software for research purposes and the customer handles...
12/30/2025, 2:26 PM
by Vino Pino
26
NuWays has apparently already updated its outlook on 12.12.2025, i.e., after the €4m directed issue, and raised the target price based on cost cuts. 3.5 (Buy) → 3.8 EUR & (Buy) It should grow, though… The gloom of H1 2025 is explained by Research at -16%, while Clinical grew an impressive...
1/14/2026, 8:38 PM
by Opa
19
The gradually departing CFO Parkkonen made a €27,448 addition to Aiforia’s capital by exercising options he received before his departure: Volume: 20,000 Average price: 1.3724 EUR. Aiforia Technologies Oyj – Johdon liiketoimet – Veli-Matti Parkkonen - Inderes For example, in the ...
1/22/2026, 9:37 AM
by Vino Pino
11
Wealth from AI has accumulated in Finland through previous success stories, such as SiloAI being sold to AMD. Why doesn’t Aiforia attract top-tier talent? This caught my eye as I’m trying to build what is otherwise a potential investment case. Academic research, references, strong...
1/6/2026, 9:11 PM
by Eituottoailmanriskiä
9
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.